Granules India
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Granules India is strategically transitioning from a volume-driven model to a focus on complex generics, which now constitute half of its revenue mix. Management's confidence stems from the successful ramp-up of its Peptide CDMO business and the expansion of its market presence in Europe and other regions. Despite facing near-term challenges such as supply chain volatility and regulatory hurdles at the Gagillapur facility, the company maintains a strong balance sheet and disciplined capital allocation, which supports ongoing R&D and product development. Vista's financial outlook reflects moderate revenue growth expectations, stable margins, and a fair valuation, with a target price indicating an expected upside of approximately 25%. The industry context remains favorable, with Indian CDMOs gaining traction amid global supply chain diversification, although competitive pricing pressures persist. Over the next 12-24 months, key opportunities include the successful commercialization of pending ANDAs and scaling specialized oncology and peptide platforms, while watchpoints include regulatory resolutions and external cost pressures that could impact margins
Why We Like This Stock
- Successful transition to complex generics, enhancing revenue mix and competitive positioning
- Strong balance sheet supports ongoing R&D and capital investments in high-value segments
- Favorable industry dynamics for Indian CDMOs amid global supply chain shifts
Things To Watch Out For
- Regulatory challenges at the Gagillapur facility could delay product launches
- Ongoing supply chain volatility and cost pressures may impact margins
- Stagnation in the US formulations business presents execution risks
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 4,506 | 4,482 | 5,366 | 5,688 | 6,302 |
| Profit Before Tax (Cr.) | 549 | 632 | 795 | 927 | 1,030 |
| PBT Margin | 12.2% | 14.1% | 1481.6% | 16.3% | 16.4% |
| Net Profit (Cr.) | 384 | 458 | 597 | 697 | 775 |
| Earnings Per Share | 15.5 | 18.5 | 24.1 | 28.1 | 31.3 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Choice Equity | ► Hold | 835 | 16-Jun-2026 |
| Elara Capital | ► Accumulate | 851 | 21-Jul-2026 |
| Emkay Global | ▲ Buy | 950 | 22-Jul-2026 |
| Motilal Oswal | ▲ Buy | 1,010 | 22-Jul-2026 |
Company Overview
Show Company Profile
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.